Global Gastric Cancer Therapy Market Outlook: Share, Application Analysis, Regional Outlook, Growth Trends, Products, Competitive Strategies and Forecasts 2018 to 2023
Orbis Research Present's Global Gastric Cancer Therapy Market Research which enhances the decision making Capabilities and helps to Create an Effective Counter Strategies to Gain Competitive Advantage
(EMAILWIRE.COM, August 30, 2018 ) The Global Gastric Cancer Therapy Market is expected to register a CAGR of 13.0% during the forecast period (2018 - 2023). Asia Pacific dominates the market, due to the growing incidence of gastric cancer in that region.
Companies Mentioned:
Bristol-Myers Squibb, Eli Lilly And Company, F. Hoffmann-La Roche Ltd, Glaxosmithkline Plc, Imugene Limited, Merck Kgaa, Novartis Ag, Ono Pharmaceuticals, Otsuka Holdings Co. Ltd, Sanofi
Get PDf Sample pages of Report at: http://www.orbisresearch.com/contacts/request-sample/2131766?utm_source=Dipali
Growing Incidence of Gastric Cancer
According to a report published by Indian Council of Medical Research in 2014, gastric cancer is the fourth leading cancer in the world, accounting for 736,000 deaths. Around 1 million new cases of gastric cancer and 0.7 million deaths due to gastric cancer are reported every year. Age-standardized incidence rates are approximately twice as high in men as in women. Presently, gastric cancer is more common in Asia, than in the United States or Europe. Notably, 42% of cases occur in China alone.
Thus, increasing incidence of gastric cancer, coupled with strong drug pipeline, and introduction of novel therapies for metastatic stomach cancer, across the world, are likely to drive the market for gastric cancer therapy.
High Cost of Cancer Therapy and Side Effects of Cancer Drugs
The global cost of cancer therapy and drugs increased from USD 91 billion to USD 113 billion, in 2016. High cost of therapy and adverse events associated with the existing cancer drugs, for treatment of stomach cancer, may hinder the global stomach cancer market. The serious side effects associated with the usage of drugs include autoimmune reactions and infusion reactions. Additionally, a large patient pool undiagnosed with gastric cancer and the lack of awareness regarding gastric cancer are likely to impede the growth of the global cancer therapy market.
Asia-Pacific to Dominate the Market
Asia-Pacific dominates the global gastric cancer therapy market, owing to high incidence of stomach cancer in that region. China is expected to show a tremendous growth for this market, during the forecast period, owing to factors, such as high prevalence of obesity, and growing awareness about diabetes care. The growing incidence of gastric cancer in China is followed by Japan and Korea. China accounts for over 40% of all new gastric cancer cases in the world, which will drive the market for gastric cancer therapy in China.
Browse complete Report at: http://www.orbisresearch.com/reports/index/global-gastric-cancer-therapy-market-segmented-by-therapy-type-end-user-and-geography-growth-trends-and-forecast-2018-2023?utm_source=Dipali
Key Developments in the Market
February 2018: Imugene, an immune oncology company announced that its cancer vaccine yields promising results in gastric cancer clinical trial studies.
September 2017: The Food and Drug Administration (FDA) approved the immunotherapy drug pembrolizumab(Keytruda®) to be used on patients with advanced gastric (stomach) cancer.
Reasons to Purchase the Report
Current and future market outlook for gastric cancer therapy in the developed and emerging markets
Analyse various perspectives on the market, with the help of Porter’s five forces analysis
The segment that is expected to dominate the market
Regions that are expected to witness the fastest growth, during the forecast period
Identify the latest developments, market shares, and strategies employed by the major market players
3 month analyst support, along with the market estimate sheet (in Excel)
Customization of the Report
This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Enquire For more details of Report at: http://www.orbisresearch.com/contacts/enquiry-before-buying/2131766?utm_source=Dipali
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients
Companies Mentioned:
Bristol-Myers Squibb, Eli Lilly And Company, F. Hoffmann-La Roche Ltd, Glaxosmithkline Plc, Imugene Limited, Merck Kgaa, Novartis Ag, Ono Pharmaceuticals, Otsuka Holdings Co. Ltd, Sanofi
Get PDf Sample pages of Report at: http://www.orbisresearch.com/contacts/request-sample/2131766?utm_source=Dipali
Growing Incidence of Gastric Cancer
According to a report published by Indian Council of Medical Research in 2014, gastric cancer is the fourth leading cancer in the world, accounting for 736,000 deaths. Around 1 million new cases of gastric cancer and 0.7 million deaths due to gastric cancer are reported every year. Age-standardized incidence rates are approximately twice as high in men as in women. Presently, gastric cancer is more common in Asia, than in the United States or Europe. Notably, 42% of cases occur in China alone.
Thus, increasing incidence of gastric cancer, coupled with strong drug pipeline, and introduction of novel therapies for metastatic stomach cancer, across the world, are likely to drive the market for gastric cancer therapy.
High Cost of Cancer Therapy and Side Effects of Cancer Drugs
The global cost of cancer therapy and drugs increased from USD 91 billion to USD 113 billion, in 2016. High cost of therapy and adverse events associated with the existing cancer drugs, for treatment of stomach cancer, may hinder the global stomach cancer market. The serious side effects associated with the usage of drugs include autoimmune reactions and infusion reactions. Additionally, a large patient pool undiagnosed with gastric cancer and the lack of awareness regarding gastric cancer are likely to impede the growth of the global cancer therapy market.
Asia-Pacific to Dominate the Market
Asia-Pacific dominates the global gastric cancer therapy market, owing to high incidence of stomach cancer in that region. China is expected to show a tremendous growth for this market, during the forecast period, owing to factors, such as high prevalence of obesity, and growing awareness about diabetes care. The growing incidence of gastric cancer in China is followed by Japan and Korea. China accounts for over 40% of all new gastric cancer cases in the world, which will drive the market for gastric cancer therapy in China.
Browse complete Report at: http://www.orbisresearch.com/reports/index/global-gastric-cancer-therapy-market-segmented-by-therapy-type-end-user-and-geography-growth-trends-and-forecast-2018-2023?utm_source=Dipali
Key Developments in the Market
February 2018: Imugene, an immune oncology company announced that its cancer vaccine yields promising results in gastric cancer clinical trial studies.
September 2017: The Food and Drug Administration (FDA) approved the immunotherapy drug pembrolizumab(Keytruda®) to be used on patients with advanced gastric (stomach) cancer.
Reasons to Purchase the Report
Current and future market outlook for gastric cancer therapy in the developed and emerging markets
Analyse various perspectives on the market, with the help of Porter’s five forces analysis
The segment that is expected to dominate the market
Regions that are expected to witness the fastest growth, during the forecast period
Identify the latest developments, market shares, and strategies employed by the major market players
3 month analyst support, along with the market estimate sheet (in Excel)
Customization of the Report
This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Enquire For more details of Report at: http://www.orbisresearch.com/contacts/enquiry-before-buying/2131766?utm_source=Dipali
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results